Big bubble size can be safely increased

Article

Undersized big-bubbles for DALK can safely be increased using blunt dissection for white-margin bubbles and ophthalmic viscosurgical device injection for clear-margin bubbles.

Undersized big-bubbles for DALK can safely be increased using blunt dissection for white-margin bubbles and ophthalmic viscosurgical device injection for clear-margin bubbles.

The investigation, headed by Dr H.D. McKee, Manchester Royal Eye Hospital, Manchester, UK, included DALK cases where air injection ruptured the posterior lamella and caused undersized big-bubbles.

In the case of white-margin bubbles that extend to the trephination margin, the bubble can be collapsed and the margins are extended by blunt dissection. However, with undersized clear-margin bubbles a gentle injection of cohesive ophthalmic viscosurgical device is administered into the bubble cavity to increase size.

Both techniques were considered safe for extending big-bubbles beyond the trephination margin for both white and clear-margin bubbles.

The abstract can be viewed in The Journal of Cornea and External Disease.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.